"ANAVEX®3-71 Phase 2 Clinical Study"
Drug Updates

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 […]

"ELYXYB Migraine Treatment"
Drug Updates

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison […]

"twiist Automated Insulin Delivery System"
Digital Health News

Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance

Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool. The twiist AID system, which will be commercialized by Sequel Med […]

Mediwave's innovative emergency response suite showcased at Global Mobile Awards
Device Digest

Mediwave Wins Global Recognition at GLOMO Awards 2024 for Health Technologies for Emergency Response

Mediwave, a leading health technology company, has been recognized as a finalist in the prestigious Global Mobile Awards (GLOMO), part of the Mobile World Congress (MWC) hosted by the GSMA in Barcelona, Spain. This recognition highlights Mediwave’s outstanding contributions in this field, particularly its innovative and integrated use of AI, the Internet of Medical Things […]

A group of pediatric patients undergoing treatment, symbolizing Fennec Pharmaceuticals and Norgine's partnership to bring PEDMARQSI® to pediatric cancer patients.
Drug Updates

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in […]

A researcher in a lab examining EEG/fMRI results on a computer screen, symbolizing Gabather AB's innovative research in psychiatric disorders treatment.
Mental Wellness

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders. The claims based on inventions from the results […]

"Biotheus and Hansoh Pharma Collaboration
Digital Health News

Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates

Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022. Biotheus will grant Hansoh Pharma a […]

"Lupin and Birmingham City University Partnership"
Digital Health News

Lupin and Birmingham City University Honour Graduates of Master’s Programme in Advancing Diabetes Care

Global pharma major Lupin Limited (Lupin) joined forces withBirmingham City University, UK (BCU) and hosted a convocation ceremony on March 9, 2024, honouringIndian healthcare professionals who completed the Master’s programme in Advancing Diabetes Care. Thisground-breaking course is tailored to empower healthcare professionals with specialized skills andtechniques to provide enhanced care for people living with diabetes.Under […]

"Angel Yeast Community Welfare Activity"
Digital Health News

Angel Yeast Hosts Community Welfare Activity in Egypt, Promoting Green Development and Cultural Exchanges 

Angel Yeast, (SH600298), the world’s leading yeast manufacturer, recently hosted a community Welfare Activity on sustainable and green development for the students at a school near its factory in Egypt and gave gifts to the students. As a socially responsible company, Angel Yeast is committed to strengthening the connection with people and local communities. The event was joined by […]

"Rezdiffra FDA Approval"
Drug Updates

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with […]